Testosterone therapy heart attack lawsuits resulted in more than 25,000 claims against major pharmaceutical manufacturers, culminating in global settlements that exceeded $1 billion by 2018. Men who suffered heart attacks, strokes, or blood clots after using products like AndroGel, Axiron, and other testosterone replacement therapies alleged that drug makers failed to adequately warn about cardiovascular risks. The litigation peaked between 2014 and 2018, with AbbVie, Eli Lilly, Pfizer, and Endo International facing thousands of individual claims consolidated into a federal multidistrict litigation in Illinois.
For example, a man in his fifties who was prescribed AndroGel for age-related low testosterone and subsequently suffered a heart attack might have had grounds to file a lawsuit if he could demonstrate the manufacturer knew about cardiovascular risks but failed to provide adequate warnings. The federal MDL has since closed, with no cases remaining in Illinois federal court as of March 2025, though the litigation’s legacy includes significant changes to product labeling and ongoing medical research into testosterone’s cardiovascular effects. This article examines the history of testosterone therapy litigation, the FDA actions that shaped these cases, major settlements and trial outcomes, the medical studies that both fueled and ultimately complicated the lawsuits, and what the current legal landscape looks like for those still considering claims.
Table of Contents
- What Caused the Wave of Testosterone Therapy Heart Attack Lawsuits?
- MDL-2545: How the Federal Litigation Was Structured
- Settlement Outcomes: What Manufacturers Paid to Resolve Claims
- Trial Verdicts: A Mixed Record for Plaintiffs
- The TRAVERSE Study: How New Research Changed Everything
- Who Filed Testosterone Therapy Lawsuits and Why?
- What the Current Legal Landscape Looks Like
- Conclusion
What Caused the Wave of Testosterone Therapy Heart Attack Lawsuits?
The testosterone therapy litigation explosion can be traced directly to a November 2013 study published in the Journal of the American Medical Association. This research linked testosterone replacement therapy to higher rates of heart attacks, strokes, and death among older men with certain pre-existing heart conditions. The study’s findings alarmed the medical community and caught the attention of both regulators and attorneys representing injured patients. The FDA responded in 2014 with a warning that men using testosterone replacement may face a two to three times increased risk for blood clots, which could potentially result in stroke or heart attack.
This regulatory acknowledgment gave substantial weight to claims that manufacturers had marketed their products without adequate safety disclosures. By 2015, the FDA required testosterone drug makers to add warning labels about potential cardiovascular risks, fundamentally altering how products like AndroGel could be promoted and prescribed. The timing mattered enormously. Testosterone therapy had been aggressively marketed throughout the early 2010s, with advertisements suggesting that “Low T” was responsible for fatigue, decreased libido, and other symptoms common to aging men. Critics argued that pharmaceutical companies had manufactured a medical condition to sell more products, targeting men who may not have had clinically low testosterone levels requiring treatment.
MDL-2545: How the Federal Litigation Was Structured
In June 2014, the U.S. Judicial Panel on Multidistrict Litigation created MDL-2545, formally titled “In Re: Testosterone Replacement Therapy Products Liability Litigation.” The consolidated cases were assigned to the Northern District of Illinois under U.S. District Judge Matthew F. Kennelly. This procedural move allowed thousands of individual lawsuits to be managed efficiently while preserving each plaintiff’s right to an individual trial if settlement negotiations failed.
The MDL structure proved particularly important given the number of defendants involved. AbbVie faced the largest share of claims due to AndroGel’s dominant market position, but Eli Lilly (maker of Axiron), Endo International, and Pfizer also defended significant numbers of cases. Consolidating pretrial proceedings—including discovery, expert witness challenges, and motions practice—prevented duplicative litigation across dozens of federal districts. However, MDL consolidation does not guarantee favorable outcomes for plaintiffs. The process can take years, and defendants with substantial resources can mount aggressive defenses. In this litigation, bellwether trials produced mixed results that influenced how both sides approached settlement negotiations.
Settlement Outcomes: What Manufacturers Paid to Resolve Claims
The testosterone therapy litigation produced substantial settlements, though the full financial picture remains partially hidden behind confidentiality agreements. Endo Pharmaceuticals provided the clearest public disclosure, allocating $200 million in June 2018 to settle approximately 1,300 federal lawsuits. This worked out to an average of roughly $154,000 per case, though individual settlement amounts varied based on the severity of injuries and strength of evidence. AbbVie, which faced the largest number of claims, settled 4,200 lawsuits in September 2018. The company did not disclose the settlement amount, making it impossible to calculate per-plaintiff averages.
Similarly, Eli Lilly resolved approximately 400 federal Axiron lawsuits in December 2017 without revealing financial terms. Industry analysts estimated that total global settlements exceeded $1 billion by 2018. These settlement figures, while substantial, should be viewed in context. Not every plaintiff received compensation, and those who did often waited years while litigation proceeded. Additionally, settlement amounts must account for attorney fees (typically 33-40% in contingency arrangements) and case expenses, meaning net recoveries to injured plaintiffs were significantly lower than gross settlement values.
Trial Verdicts: A Mixed Record for Plaintiffs
The bellwether trial process produced dramatic headlines but ultimately favored defendants more often than plaintiffs. The first three bellwether trials resulted in more than $290 million in initial verdicts, suggesting that juries were receptive to claims that manufacturers had failed to adequately warn about cardiovascular risks. However, this early momentum did not hold. AbbVie’s trial record illustrates the litigation’s complexity.
The company faced six trials, winning four and losing two. One particularly notable $140 million verdict against AbbVie did not survive appeal, demonstrating that even substantial jury awards can be reversed on legal grounds. Across all defendants, the overall trial record showed defendants winning nine cases (36%) while plaintiffs prevailed in only three (12%), with the remainder settling or being otherwise resolved. These statistics highlight an important limitation for potential plaintiffs: filing a lawsuit does not guarantee recovery, even when FDA warnings and medical studies suggest a connection between the product and the alleged harm. Juries considered competing expert testimony, individual medical histories, and whether plaintiffs had pre-existing conditions that could explain their cardiovascular events independent of testosterone use.
The TRAVERSE Study: How New Research Changed Everything
The legal and regulatory landscape shifted dramatically with the publication of the TRAVERSE study, a large-scale clinical trial that enrolled 5,246 men to examine testosterone therapy’s cardiovascular effects. The study found that testosterone therapy was “noninferior to placebo” for major adverse cardiac events, with a hazard ratio of 0.96 and a 95% confidence interval of 0.78 to 1.17. In plain terms, the study did not find that testosterone therapy increased heart attack or stroke risk compared to inactive treatment. This research, conducted over a mean duration of 22 months, prompted the FDA to update its position.
Product labels no longer include a boxed warning about increased cardiovascular risk based on the TRAVERSE study results. For ongoing and potential litigation, this development complicated plaintiffs’ ability to establish that testosterone therapy caused their injuries. The TRAVERSE study illustrates a broader challenge in pharmaceutical litigation: scientific understanding evolves over time, and studies that appear to establish causation may be contradicted by subsequent research. Plaintiffs who filed claims based on the 2013 JAMA study faced defendants who could point to later research suggesting the earlier findings were incomplete or incorrect.
Who Filed Testosterone Therapy Lawsuits and Why?
A review of legal cases filed between 2000 and 2024 reveals interesting patterns in testosterone-related litigation. During 2000-2010, only three cases were filed, reflecting the therapy’s relatively lower profile before aggressive direct-to-consumer marketing campaigns. Between 2011 and 2023, the number jumped to 22 cases in the reviewed dataset, coinciding with both increased prescriptions and heightened awareness of potential risks.
The harms alleged in these cases varied significantly. Withholding testosterone accounted for 40% of claims—a category that seems counterintuitive but reflects lawsuits by patients who believed they were wrongly denied therapy. Prostate cancer allegations represented 16% of cases, death claims 12%, cardiac events 12%, and psychiatric effects 8%. This distribution suggests that cardiovascular claims, while prominent in media coverage, represented only a portion of the overall litigation landscape.
What the Current Legal Landscape Looks Like
As of March 2025, MDL-2545 has closed with no federal cases remaining in Illinois federal court. This does not mean all testosterone-related litigation has ended—individual cases may proceed in state courts, and new claims can theoretically be filed—but the era of mass federal litigation appears to have concluded. The combination of major settlements, mixed trial results, and the TRAVERSE study’s findings have significantly reduced the litigation’s momentum.
For individuals who believe they suffered cardiovascular harm from testosterone therapy, the current environment presents challenges. The FDA’s updated labeling, which no longer includes boxed cardiovascular warnings, makes it harder to argue that manufacturers failed to provide adequate warnings. Additionally, statutes of limitations may bar claims for injuries that occurred years ago but were not timely filed.
Conclusion
The testosterone therapy heart attack litigation represented one of the largest pharmaceutical mass torts of the 2010s, with more than 25,000 lawsuits filed and settlements exceeding $1 billion. The litigation was driven by early medical studies suggesting cardiovascular risks, FDA warnings requiring label changes, and aggressive marketing that critics argued pushed testosterone therapy to men who did not medically need it.
However, the litigation’s ultimate legacy is complicated. While some plaintiffs received substantial compensation, defendants won the majority of cases that went to trial, and the TRAVERSE study has since called into question the scientific foundation underlying many claims. For those still considering whether they have a viable testosterone therapy lawsuit, consulting with an attorney who can evaluate the specific facts—including timing, medical history, and applicable statutes of limitations—remains the essential first step.